-
1
-
-
0001162529
-
Leflunomide: A novel immunomodulating drug
-
Lewis AJ, Furst DE, eds. New York: Marcel Dekker
-
Bartlett RR, Campion G, Musikic P, Schleyerbach R, Zielinski T, Schlorlemmer H-U. Leflunomide: a novel immunomodulating drug. In: Lewis AJ, Furst DE, eds. Nonsteroidal anti-inflammatory drugs. New York: Marcel Dekker, 1994.
-
(1994)
Nonsteroidal Anti-inflammatory Drugs
-
-
Bartlett, R.R.1
Campion, G.2
Musikic, P.3
Schleyerbach, R.4
Zielinski, T.5
Schlorlemmer, H.-U.6
-
2
-
-
0025202270
-
Effects of leflunomide on glomeronephritis induced by antibasement membrane antibody in rats
-
Ogawa T, Inazu M, Gotol K, Hayashi S. Effects of leflunomide on glomeronephritis induced by antibasement membrane antibody in rats. Agents Actions 1990; 31: 321.
-
(1990)
Agents Actions
, vol.31
, pp. 321
-
-
Ogawa, T.1
Inazu, M.2
Gotol, K.3
Hayashi, S.4
-
3
-
-
0021957656
-
Immunopharmacological profile of a novel isoxazol derivative, HWA486, with potential antirheumatic activity. I. Disease modifying action on adjuvant arthritis of the rat
-
Bartlett RR, Schleyerbach R. Immunopharmacological profile of a novel isoxazol derivative, HWA486, with potential antirheumatic activity. I. Disease modifying action on adjuvant arthritis of the rat. Int J Immunopharmacol 1985; 7: 7.
-
(1985)
Int J Immunopharmacol
, vol.7
, pp. 7
-
-
Bartlett, R.R.1
Schleyerbach, R.2
-
4
-
-
0026589680
-
Immunomodulation of proteoglycan-induced polyarthritis by leflunomide
-
Giant TT, Fülöp C, Mikecz K, Buzar G, Erhardt P. Immunomodulation of proteoglycan-induced polyarthritis by leflunomide. Int J Immunopharmacol 1992; 23: 105.
-
(1992)
Int J Immunopharmacol
, vol.23
, pp. 105
-
-
Giant, T.T.1
Fülöp, C.2
Mikecz, K.3
Buzar, G.4
Erhardt, P.5
-
5
-
-
0025234002
-
Drug actions on delayed-type hypersensitivity in rats with developing and established adjuvant arthritis
-
Hambleton P, McMahon S. Drug actions on delayed-type hypersensitivity in rats with developing and established adjuvant arthritis. Agents Actions 1990; 29: 328.
-
(1990)
Agents Actions
, vol.29
, pp. 328
-
-
Hambleton, P.1
McMahon, S.2
-
6
-
-
0023553077
-
Disease modifying activity of HWA486 in rat adjuvant arthritis
-
Pasternak RD, Wadopian NS, Wright RN, Siminoff P, Gylys JA, Buyniski J. Disease modifying activity of HWA486 in rat adjuvant arthritis. Agents Actions 1986; 21: 241.
-
(1986)
Agents Actions
, vol.21
, pp. 241
-
-
Pasternak, R.D.1
Wadopian, N.S.2
Wright, R.N.3
Siminoff, P.4
Gylys, J.A.5
Buyniski, J.6
-
7
-
-
0023025053
-
Disease modifying activity of HWA486 on the development of SLE in MLR/lpr mice
-
Popovic S, Bartlett RR. Disease modifying activity of HWA486 on the development of SLE in MLR/lpr mice. Agents Actions 1986; 19: 313.
-
(1986)
Agents Actions
, vol.19
, pp. 313
-
-
Popovic, S.1
Bartlett, R.R.2
-
8
-
-
0024787777
-
Leflunomide (HWA486) inhibits experimental autoimmune tubulointerstitial nephritis in rats
-
Thoenes GH, Sitter T, Langer KH, Bartlett RR, Schleyerbach R. Leflunomide (HWA486) inhibits experimental autoimmune tubulointerstitial nephritis in rats. Int J Immunopharmacol 1989; 11: 921.
-
(1989)
Int J Immunopharmacol
, vol.11
, pp. 921
-
-
Thoenes, G.H.1
Sitter, T.2
Langer, K.H.3
Bartlett, R.R.4
Schleyerbach, R.5
-
9
-
-
0013593986
-
Efficacy of novel immunomodulators leflunomide and rapamycin in autoimmune uveitis
-
Smith-Lang L, Glaser RL, Miller ST, et al. Efficacy of novel immunomodulators leflunomide and rapamycin in autoimmune uveitis. FASEB J 1992; 21: 284.
-
(1992)
FASEB J
, vol.21
, pp. 284
-
-
Smith-Lang, L.1
Glaser, R.L.2
Miller, S.T.3
-
10
-
-
0023554171
-
The use of murine chronic graft versus rejection (cGvH) disease, a model for systemic lupus erythematosus (SLE), for drug discovery
-
Popovic S, Bartlett RR. The use of murine chronic graft versus rejection (cGvH) disease, a model for systemic lupus erythematosus (SLE), for drug discovery. Agents Actions 1987; 21: 284.
-
(1987)
Agents Actions
, vol.21
, pp. 284
-
-
Popovic, S.1
Bartlett, R.R.2
-
11
-
-
0028235690
-
An evaluation of leflunomide in the canine renal transplantation model
-
McChesney LP, Xiao F, Sankary HN, et al. An evaluation of leflunomide in the canine renal transplantation model. Transplantation 1994; 57: 1717.
-
(1994)
Transplantation
, vol.57
, pp. 1717
-
-
McChesney, L.P.1
Xiao, F.2
Sankary, H.N.3
-
12
-
-
0028816714
-
Leflunomide (HWA486) and its analog suppress T- and B-cell proliferation in vitro, acute rejection, ongoing rejection and antidonor antibody synthesis in mouse, rat and cynomolgus monkey transplant recipients as well as arterial intimai thickening after balloon catheter injury
-
Morris RE, Huang X, Cao W, Zheng B, Shorthouse RA. Leflunomide (HWA486) and its analog suppress T- and B-cell proliferation in vitro, acute rejection, ongoing rejection and antidonor antibody synthesis in mouse, rat and cynomolgus monkey transplant recipients as well as arterial intimai thickening after balloon catheter injury. Transplant Proc 1995; 27: 430.
-
(1995)
Transplant Proc
, vol.27
, pp. 430
-
-
Morris, R.E.1
Huang, X.2
Cao, W.3
Zheng, B.4
Shorthouse, R.A.5
-
13
-
-
0026060988
-
Prevention of kidney and skin graft rejection in rats by leflunomide, a new immunomodulating agent
-
Küchle CCA, Thoenes GH, Langer KH, Schlorlemmer HU, Bartlett RR, Schleyerbach R. Prevention of kidney and skin graft rejection in rats by leflunomide, a new immunomodulating agent. Transplant Proc 1991; 23: 1083.
-
(1991)
Transplant Proc
, vol.23
, pp. 1083
-
-
Küchle, C.C.A.1
Thoenes, G.H.2
Langer, K.H.3
Schlorlemmer, H.U.4
Bartlett, R.R.5
Schleyerbach, R.6
-
14
-
-
0028354267
-
Leflunomide in experimental transplantation. Control of rejection and alloantibody production, reversal of acute rejection, and interaction with cyclosporine
-
Williams JW, Xiao F, Foster P, et al. Leflunomide in experimental transplantation. Control of rejection and alloantibody production, reversal of acute rejection, and interaction with cyclosporine. Transplantation 1994; 57: 1223.
-
(1994)
Transplantation
, vol.57
, pp. 1223
-
-
Williams, J.W.1
Xiao, F.2
Foster, P.3
-
15
-
-
0027970997
-
Leflunomide controls rejection in hamster to rat cardiac xenografts
-
Xiao F, Chong AS-F, Foster P, et al. Leflunomide controls rejection in hamster to rat cardiac xenografts. Transplantation 1994; 58: 826.
-
(1994)
Transplantation
, vol.58
, pp. 826
-
-
Xiao, F.1
Chong, A.S.-F.2
Foster, P.3
-
16
-
-
0028816714
-
Studies in experimental models of chronic rejection: Use of rapamycin (Sirolimus) and isoxazole derivatives (leflunomide and its analogue) for the suppression of grat vascular disease and obliterative bronchiolitis
-
Morris RE, Huang X, Gregory CR, et al. Studies in experimental models of chronic rejection: use of rapamycin (Sirolimus) and isoxazole derivatives (leflunomide and its analogue) for the suppression of grat vascular disease and obliterative bronchiolitis. Transplant Proc 1995; 27: 445.
-
(1995)
Transplant Proc
, vol.27
, pp. 445
-
-
Morris, R.E.1
Huang, X.2
Gregory, C.R.3
-
17
-
-
8944263494
-
Pharmacological intervention of chronic transplant rejection
-
in press
-
Xiao F, Chong AS-F, Shen J, et al. Pharmacological intervention of chronic transplant rejection. Transplantation (in press).
-
Transplantation
-
-
Xiao, F.1
Chong, A.S.-F.2
Shen, J.3
-
18
-
-
9044240074
-
Molecular mechanism of suppression of arterial intimai thickening by lelunomide (LFM): Demonstration of direct antiproliferative effect on marine vascular smooth muscle cells (M-VSMC) in vitro and antagonism of action by uridine
-
Nair R, Cao W, Morris R. Molecular mechanism of suppression of arterial intimai thickening by lelunomide (LFM): demonstration of direct antiproliferative effect on marine vascular smooth muscle cells (M-VSMC) in vitro and antagonism of action by uridine. J Heart Lung Transplant 1995; (suppl) : 554.
-
(1995)
J Heart Lung Transplant
, Issue.SUPPL.
, pp. 554
-
-
Nair, R.1
Cao, W.2
Morris, R.3
-
19
-
-
0027279125
-
Leflunomide, a novel immunosuppressive agent
-
Chong AS-F, Finnegan A, Jiang X, et al. Leflunomide, a novel immunosuppressive agent. Transplantation 1993; 55: 1361.
-
(1993)
Transplantation
, vol.55
, pp. 1361
-
-
Chong, A.S.-F.1
Finnegan, A.2
Jiang, X.3
-
20
-
-
0027485719
-
Modulation of protein tyrosine phosphorylation during G1/S transition in activated human T-lymphoblasts
-
Churcher Y, Moss S. E. Modulation of protein tyrosine phosphorylation during G1/S transition in activated human T-lymphoblasts. J Biol Chem 1993; 268: 26144.
-
(1993)
J Biol Chem
, vol.268
, pp. 26144
-
-
Churcher, Y.1
Moss, S.E.2
-
21
-
-
0021271862
-
The interleukin-2 T-cell system: A new cell growth model
-
Cantrell DA, Smith KA. The interleukin-2 T-cell system: a new cell growth model. Science 1984; 224: 1312.
-
(1984)
Science
, vol.224
, pp. 1312
-
-
Cantrell, D.A.1
Smith, K.A.2
-
22
-
-
0026081972
-
Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes
-
Kahan BD, Gibbons S, Tejpal N, Stepkowski SM, Chou T. Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes. Transplantation 1991; 51: 232.
-
(1991)
Transplantation
, vol.51
, pp. 232
-
-
Kahan, B.D.1
Gibbons, S.2
Tejpal, N.3
Stepkowski, S.M.4
Chou, T.5
-
23
-
-
0017076160
-
Derivation and properties of Michaelis-Menton type and Hill type equations for reference ligands
-
Chou TC. Derivation and properties of Michaelis-Menton type and Hill type equations for reference ligands. J Theor Biol 1976; 59: 253.
-
(1976)
J Theor Biol
, vol.59
, pp. 253
-
-
Chou, T.C.1
-
24
-
-
0000994406
-
Analysis of combined drug effect: A new look at a very old problem
-
Chou TC, Talalay P. Analysis of combined drug effect: a new look at a very old problem. Trends Pharmacol Sci 1983; 4: 450.
-
(1983)
Trends Pharmacol Sci
, vol.4
, pp. 450
-
-
Chou, T.C.1
Talalay, P.2
-
25
-
-
0026653158
-
Immunopharmacology of new xenobiotic immunosuppressive molecules
-
Morris RE. Immunopharmacology of new xenobiotic immunosuppressive molecules. Semin Nephrol 1992; 12: 304.
-
(1992)
Semin Nephrol
, vol.12
, pp. 304
-
-
Morris, R.E.1
-
26
-
-
0029098762
-
Leflunomide, a reversible inhibitor of pyrimidine biosynthesis?
-
Zielinski T, Zeitter D, Müllner S, Bartlett RR. Leflunomide, a reversible inhibitor of pyrimidine biosynthesis? Inflammation Res 1995; 44 (suppl): S207.
-
(1995)
Inflammation Res
, vol.44
, Issue.SUPPL.
-
-
Zielinski, T.1
Zeitter, D.2
Müllner, S.3
Bartlett, R.R.4
-
27
-
-
0027252642
-
Inhibitors of de novo purine and pyrimidine synthesis as immunosuppressive drugs
-
Allison AC, Eugui EM. Inhibitors of de novo purine and pyrimidine synthesis as immunosuppressive drugs. Transplant Proc 1993; 25: 8.
-
(1993)
Transplant Proc
, vol.25
, pp. 8
-
-
Allison, A.C.1
Eugui, E.M.2
-
28
-
-
0028004196
-
Novel mechanisms of brequinar sodium immunosuppression on T cell activation
-
Forrest TL, Ware RE, Howard T, Jaffee BD, Denning SM. Novel mechanisms of brequinar sodium immunosuppression on T cell activation. Transplantation 1994; 58: 920.
-
(1994)
Transplantation
, vol.58
, pp. 920
-
-
Forrest, T.L.1
Ware, R.E.2
Howard, T.3
Jaffee, B.D.4
Denning, S.M.5
-
29
-
-
0029052321
-
Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide
-
Xu X, Willaims JW, Bremer EG, Finnegan A, Chong AS-F. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J Biol Chem 1995; 280: 12398.
-
(1995)
J Biol Chem
, vol.280
, pp. 12398
-
-
Xu, X.1
Willaims, J.W.2
Bremer, E.G.3
Finnegan, A.4
Chong, A.S.-F.5
-
30
-
-
0027203670
-
The antilymphocytic activity of brequinar sodium and its potentiation by cytidine. Effects on lymphocyte proliferation and cytokine production
-
Woo J, Kemster B, Tamura K, Starzl TE, Thomson AW. The antilymphocytic activity of brequinar sodium and its potentiation by cytidine. Effects on lymphocyte proliferation and cytokine production. Transplantation 1993; 56: 374.
-
(1993)
Transplantation
, vol.56
, pp. 374
-
-
Woo, J.1
Kemster, B.2
Tamura, K.3
Starzl, T.E.4
Thomson, A.W.5
-
31
-
-
0027786825
-
Toward a rational design of clinical trials of immunosuppressive agents in transplantation
-
Kahan BD. Toward a rational design of clinical trials of immunosuppressive agents in transplantation. Immunol Rev 1993; 136: 29.
-
(1993)
Immunol Rev
, vol.136
, pp. 29
-
-
Kahan, B.D.1
-
32
-
-
0024442393
-
A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin
-
Siekiera JJ, Hung SHY, Poe M, Lin CS, Siganl NH. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature 1989; 341: 755.
-
(1989)
Nature
, vol.341
, pp. 755
-
-
Siekiera, J.J.1
Hung, S.H.Y.2
Poe, M.3
Lin, C.S.4
Siganl, N.H.5
-
33
-
-
0024472603
-
The immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase
-
Harding MW, Galat A, Uehling DE, Schreiber SL. The immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature 1989; 341: 758.
-
(1989)
Nature
, vol.341
, pp. 758
-
-
Harding, M.W.1
Galat, A.2
Uehling, D.E.3
Schreiber, S.L.4
-
34
-
-
0026012156
-
FK506-binding protein proline rotamase is a target for the immunosuppressant rapamycin in yeast
-
Heitman J, Movva NR, Heistand C, Hall MN. FK506-binding protein proline rotamase is a target for the immunosuppressant rapamycin in yeast. Proc Natl Acad Sci USA 1991; 88: 1948.
-
(1991)
Proc Natl Acad Sci USA
, vol.88
, pp. 1948
-
-
Heitman, J.1
Movva, N.R.2
Heistand, C.3
Hall, M.N.4
-
35
-
-
0025022365
-
The immunosuppressive macrolides FK and rapamycin act as reciprocal antagonists in murine T cells
-
Dumont FJ, Melino MR, Staruch MJ, Koprak SL, Fischer A, Sigal NH. The immunosuppressive macrolides FK and rapamycin act as reciprocal antagonists in murine T cells. J Immunol 1990; 144: 1418.
-
(1990)
J Immunol
, vol.144
, pp. 1418
-
-
Dumont, F.J.1
Melino, M.R.2
Staruch, M.J.3
Koprak, S.L.4
Fischer, A.5
Sigal, N.H.6
|